Focus of the Report: This Health Technology Assessment focuses on evaluating the effectiveness and safety of the LiverMultiScan compared with other imaging and blood marker tests for assessment of liver fibrosis or steatosis in patients who have known or suspected non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).
Technology Description: LiverMultiScan is a non-invasive diagnostic aid for liver disorders that uses multiparametric magnetic resonance imaging (MRI) to evaluate liver tissue, providing quantitative measures of liver fat and correlates of cell death, fibrosis, and inflammation.
Controversy: LiverMultiScan is a relatively new technique that has not been adequately compared with established methods for evaluation of patients who have known or suspected NAFLD or NASH.
Is LiverMultiScan testing effective for diagnosis or monitoring of patients who have known or suspected NAFLD or NASH?
How does LiverMultiScan compare with conventional techniques for diagnosis or monitoring of NAFLD or NASH?
Is LiverMultiScan safe for diagnosis and monitoring in patients who have known or suspected NAFLD or NASH?
Have definitive patient selection criteria been identified for LiverMultiScan for diagnosis or monitoring in patients who have known or suspected NAFLD or NASH?
If you have a Hayes login, click here to view the full report on the Knowledge Center.